Modafinil (Provigil)

<p>Welcome back! Today, we are looking at Modafinil and it&#39;s nuanced use in psychiatry.</p><p><br></p><p>References:</p><ol><li><p>Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda</a><em>docs/label/2015/020717s037s038lbl.pdf</em></p></li><li><p>Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.</p></li><li><p>Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642</p></li><li><p>Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4</p></li><li><p>Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560</p></li><li><p>Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119</p></li><li><p>Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859</p></li></ol>